Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Haemonetics Corporation(HAE)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for HAE
11/10/2026: HAE (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Haemonetics Corporation is a specialized medical technology company that provides critical blood management and diagnostic solutions to blood centers, plasma collectors, and hospitals. Its business is built on a strong foundation of automated apheresis systems and recurring revenue from disposables, which provides a level of operational stability. The company's primary growth opportunity lies in expanding its footprint in specialized hospital diagnostics through recent strategic acquisitions. However, it faces competitive risks from larger medical device firms and potential volatility related to procedural volumes and regulatory requirements. It may suit growth-oriented investors who monitor the adoption of its digital platforms and the successful integration of newly acquired diagnostic technologies.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | The company targets sustainable growth in plasma collection and specialized hospital diagnostics. |
| Momentum investor | Mixed fit | Momentum depends on market sentiment regarding procedural volumes and plasma collection trends. |
| Value investor | Mixed fit | Valuation is often tied to growth potential rather than deep-value metrics. |
| Dividend investor | Weak fit | The company does not pay a cash dividend. |
| Low-risk investor | Mixed fit | As a medical device company, it faces regulatory and execution risks inherent in the sector. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | Medium | The stock price can fluctuate based on sector-wide shifts in medical device valuations. |
| Valuation risk | Medium | Growth expectations are often priced into the stock, leaving little room for earnings misses. |
| Competition risk (Plasma/Hospital Devices) | Medium / high | Intense competition from established global medical device firms impacts pricing power. |
| Business quality | Strong | The company holds strong, sticky market positions in specific niche technology areas. |
| Dividend income | Low / none | Income-focused investors will not find this stock suitable for cash yield. |
| Execution risk | Medium | Success relies heavily on integrating acquisitions and expanding device adoption in hospitals. |
Price Behavior
Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.
Moderately Choppy
The stock has experienced noticeable price swings while retaining some directional structure.
Analysis of Past Performance
Type Stock | Historic Profit 8.63% | Avg. Invested days 51 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Advisory Rating  | Upturn Advisory Performance  2.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 11/10/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 5.38B USD | Price to earnings Ratio 52.31 | 1Y Target Price 137.5 |
Price to earnings Ratio 52.31 | 1Y Target Price 137.5 | ||
Volume (30-day avg) 765.0K shares | Beta 0.59 | 52 Weeks Range 51.00 - 132.00 | Updated Date 11/10/2026 |
52 Weeks Range 51.00 - 132.00 | Updated Date 11/10/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) 2.26 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Plasma Collection | Automated apheresis devices and associated disposables sold to plasma collection centers. | This is a primary revenue driver, benefiting from the consistent global demand for plasma-derived therapies. |
| Hospital & Diagnostics | Surgical blood management devices and point-of-care diagnostic analyzers. | This segment provides technology to hospitals to help improve surgical outcomes and manage blood usage. |
| Geography (Global) | Sales across North America, Europe, and emerging markets. | Operations are globally diversified, reducing reliance on any single regional economy. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2026-11-05 | When Before Market | Estimate 1.3 | Actual 1.35 |
Profitability
Profit Margin 7.52% | Operating Margin (TTM) 21.65% |
Management Effectiveness
Return on Assets (TTM) 6.71% | Return on Equity (TTM) 11.89% |
Valuation
Trailing PE 52.31 | Forward PE 22.78 | Enterprise Value 6.25B | Price to Sales(TTM) 3.89 |
Enterprise Value 6.25B | Price to Sales(TTM) 3.89 | ||
Enterprise Value to Revenue 4.57 | Enterprise Value to EBITDA 22.07 | Shares Outstanding 45.54M | Shares Floating 44.93M |
Shares Outstanding 45.54M | Shares Floating 44.93M | ||
Percent Insiders 1.26 | Percent Institutions 110.2 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.